Highlights
Highlights
-
Candidate malaria vaccine provides lasting protection in NIH-sponsored trials
Approach could have role in preventing malaria in pregnancy.
-
Immunotherapy approach shows potential in some people with metastatic solid tumor
NIH researchers achieved tumor shrinkage in three of seven patients with colorectal cancers.
-
Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma
Combination therapy developed by NIH researchers demonstrates the power of precision medicine.
-
NIH-funded clinical trial links frequent anger to increased risk of heart disease
Findings demonstrate impairment of blood vessel function; may lead to heart attack, stroke.
-
Hearing aids slow cognitive decline in people at high risk
Hearing aids cut the rate of cognitive decline by nearly half in older adults at high risk of dementia.
-
NIH clinical trial of tuberculous meningitis drug regimen begins
Six-month multidrug regimen being evaluated against standard treatment.
-
Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder Cancer
For people with advanced bladder cancer, combining enfortumab (Padcev) and pembrolizumab (Keytruda) should be the new standard initial treatment, new clinical trial results suggest.
-
Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas
The CAR T-cell therapy axicabtagene ciloleucel (Yescarta) improved survival for people with large B-cell lymphoma that was not responding to initial treatment or had relapsed quickly, according to new data from the ZUMA-7 trial
-
Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients
NCI has helped launch the Pragmatica-Lung Study, a phase 3 randomized clinical trial of a two-drug combination to treat patients with advanced non-small cell lung cancer. The simplified trial design aims to increase accessibility for participants.
-
NIH study finds that immunotherapy substantially increases survival of people with lymphomatoid granulomatosis
Patients treated with interferon alfa-2b lived for decades after diagnosis in Phase 2 trial.
This page last reviewed on
